HomeCONGRESS

CONGRESS

View Category
Coronary disease

Impella: A Revolutionary Device Being Questioned

Observational studies (with their subsequent limitations) show a possible increase in adverse events and costs with the...
solaci -
Learn More
Events

The 17th Annual Meeting of the Venezuelan Society of Interventional Cardiology is Coming

On Saturday December 14, 2019, the 17th Meeting of the Venezuelan Society of Interventional Cardiology (SOVECI) will be...
solaci -
Learn More
Acute coronary syndromes

AHA 2019 | COMPLETE: Complete Revascularization Is Superior since It Treats Other Vulnerable Plaque

This COMPLETE sub-study using optical coherence tomography (OCT) showed the prevalence of vulnerable lesions other than the...
solaci -
Learn More
STRUCTURAL HEART DISEASE

AHA 2019 | Sapien vs Evolut: A Head-to-Head Study Seems Mandatory

Two French registries have carried out a propensity matched comparison which suggest differences between balloon-expandable valves (BEV)...
solaci -
Learn More
Carotid

AHA 2019 | Treat Stroke to Target: Post-Stroke Aggressive Therapy with Statins

Indicating statins to reach more aggressive LDL goals in patients that have suffered transient ischemic attack or...
solaci -
Learn More
Chronic Ischemic cardiopathy

AHA 2019 | ISCHEMIA-CKD: Chronic Kidney Disease and Stable Coronary Disease

Among patients in the main ISCHEMIA trial, those with chronic kidney disease are a particularly high-risk subgroup....
solaci -
Learn More
Antithrombotic Anticoagulants

AHA 2019 | GALILEO: Rivaroxaban After TAVI, Another Nice Theory that Clashes with Reality

In patients without formal indication for oral anticoagulation after successful transcatheter aortic valve implantation (TAVI), a treatment...
solaci -
Learn More
Other

AHA 2019 | DAPA-HF: Dapagliflozin Effective for all Heart Failure Subgroups

SGLT2 inhibitor dapagliflozin had a consistent impact regardless of glycemic level, age, or general health status. Dapagliflozin was...
solaci -
Learn More